Clinical experience with thymoglobulin and antithymocyte globulin-fresenius as induction therapy in renal transplant patients: A retrospective study

Experimental and Clinical Transplantation

Volumn 11, Issue 5, 2013, Pages 418-422

  Cicora, Federico ^a   Mos, Fernando ^a   Paz, Marta ^a   Roberti, Javier ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

Argentina; ATG; Immunosuppression; Kidney; Transplant

Indexed keywords

ANTITHYMOCYTE GLOBULIN FRESENIUS; CREATININE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DEATH; DECEASED DONOR; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; KIDNEY DONOR; KIDNEY GRAFT; LEUKOCYTE COUNT; LIVING DONOR; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT;

ADULT; ANTILYMPHOCYTE SERUM; BIOLOGICAL MARKERS; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885671958     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2013.0027     Document Type: Article

References (16)

1. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-1977.
2. Benítez CE, Puig-Pey I, López M, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant. 2010;10(10):2296-2304. doi: 10. 1111/j. 1600-6143. 2010. 03164. x.
3. Gavela Martínez E, Sancho Calabuig A, Escudero Quesada V, et al. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors. Transplant Proc. 2008;40(9):2900-2902. doi: 10. 1016/j. transproceed. 2008. 08. 082.
4. Gaber AO, Matas AJ, Henry ML, et al. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation. 2012;94(4):331-337.
5. Gurk-Turner C, Airee R, Philosophe B, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation. 2008;85(10):1425-1430. doi: 10. 1097/TP. 0b013e31816dd596.
6. Trofe-Clark J, Reese PP, Patel HJ, et al. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes. Transplantation. 2012;94(5):506-512.
7. Urbanova M, Brabcova I, Girmanova E, Zelezny F, Viklicky O. Differential regulation of the nuclear factor-êB pathway by rabbit antithymocyte globulins in kidney transplantation. Transplantation. 2012;93(6):589-596. doi: 10. 1097/TP. 0b013e31824491aa.
8. Aull MJ, Suthanthiran M. Transplantation: Personalizing induction therapy in kidney transplantation. Nat Rev Nephrol. 2009;5(11):619-620. doi: 10. 1038/nrneph. 2009. 164.
9. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation. 2001;71(1):53-58.
10. Schulz T, Papapostolou G, Schenker P, Kapischke M. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin. Transplant Proc. 2005;37(2):1301-1304.
11. Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation. 2004;77(7):1029-1033.
12. Popow I, Leitner J, Majdic O, et al. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation. 2012;93(1):32-40. doi: 10. 1097/ TP. 0b013e31823 bb664.
13. Brennan DC, Flavin K, Lowell JA, et al. A randomized, doubleblinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67(7):1011-1018. Erratum in: Transplantation 1999;67(10):1386.
14. Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation. 2005;79(8):958-963.
15. Kim JM, Jang HR, Ko JS, et al. Comparison between thymoglobulin and ATGAM as an induction agent in adult kidney transplantation: a single-center experience. Transplant Proc. 2012;44(1):171-174. doi: 10. 1016/j. transproceed. 2011. 11. 061.
16. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009;69(11):1483-1512. doi: 10. 2165/00003495-200969110-00007.